What Is KPV?

KPV is a peptide that has become increasingly popular in conversations about inflammation, gut health, skin wellness and tissue recovery.

It is especially well known for its relationship to alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in immune regulation, pigmentation and the body’s response to inflammation. KPV contains only three amino acids but appears to retain several of the anti-inflammatory properties associated with the larger peptide.

KPV may be included in compounded peptide therapies prescribed by some healthcare providers. Here’s what we currently know about how it works, what researchers have studied and what to expect if you are considering treatment.

What Is KPV?

KPV is a tripeptide made from three amino acids:

• Lysine
• Proline
• Valine

The peptide’s name comes from the standard one-letter abbreviations for those amino acids: K for lysine, P for proline and V for valine.

KPV corresponds to amino acids 11 through 13 at the end of alpha-melanocyte-stimulating hormone, commonly called alpha-MSH. Alpha-MSH is a naturally occurring peptide involved in inflammatory signaling, immune activity, skin pigmentation and other biological processes.

Researchers discovered that this short KPV sequence appears to retain much of alpha-MSH’s anti-inflammatory activity without the portion of the larger peptide primarily responsible for stimulating pigment production.

KPV has since been studied in connection with:

• Inflammatory signaling
• Intestinal and digestive health
• Skin inflammation
• Wound healing
• Immune regulation
• Epithelial-barrier support
• Antimicrobial activity
• Recovery-focused peptide therapy

Its small size and focused biological activity have made KPV an area of interest within both immunology research and regenerative wellness.

The History of KPV

The scientific history of KPV begins with research into alpha-MSH.

Alpha-MSH was initially recognized for its role in stimulating melanin production. Researchers later discovered that the peptide also influences inflammation, immune-cell activity, fever and the body’s response to infection or tissue damage.

Scientists began examining different sections of alpha-MSH to determine which amino-acid sequences were responsible for these effects.

In 1989, researchers reported that alpha-MSH’s three-amino-acid terminal sequence retained anti-inflammatory activity in an animal model. This finding demonstrated that the complete alpha-MSH molecule was not necessarily required to influence certain inflammatory responses.

Research during the following decades explored how KPV interacts with:

• Pro-inflammatory cytokines
• Nuclear factor kappa B, commonly called NF-kB
• Mitogen-activated protein kinase pathways
• Intestinal epithelial cells
• Immune cells
• Peptide transporters in the digestive tract
• Microorganisms associated with infection
  
• Wound-healing processes

KPV became particularly interesting because its biological activity appears to differ from the pigmentation-related effects associated with full-length alpha-MSH.

Today, KPV is most commonly discussed in connection with inflammatory balance, gastrointestinal wellness, skin health and tissue recovery.

How Does KPV Work?

KPV appears to influence several connected processes involved in inflammation, immune signaling and barrier-tissue recovery.

Inflammatory Signaling

Inflammation is a normal part of the body’s defense and repair systems. It helps the immune system respond to infections, injuries and damaged tissue.

Problems can develop when inflammatory signals remain elevated or become poorly regulated.

Experimental research suggests that KPV may help regulate several pathways involved in producing and maintaining an inflammatory response.

One of the most important is NF-kB, a transcription factor that helps control the expression of genes associated with inflammation, immune activity and cellular stress.

Laboratory studies have found that KPV can inhibit NF-kB activation under certain experimental conditions. This activity may reduce the production of inflammatory signaling molecules such as:

• Tumor necrosis factor alpha
• Interleukin-1 beta
• Interleukin-6
• Interleukin-8
• Other pro-inflammatory cytokines and chemokines

Rather than targeting one isolated inflammatory molecule, KPV appears to interact with signaling processes that influence multiple parts of the inflammatory response.

MAP Kinase Pathways

KPV has also been studied for its effects on mitogen-activated protein kinases, commonly called MAP kinases.

These signaling pathways help cells respond to inflammation, physical stress, infection and changes in their surrounding environment. They also influence processes such as cell growth, survival and cytokine production.

Laboratory research involving intestinal epithelial and immune cells found that KPV reduced the activation of certain MAP kinase pathways alongside NF-kB.

This combination may help explain why researchers have observed anti-inflammatory activity across more than one type of cell or tissue.

Intestinal Peptide Transport

One of the most extensively studied features of KPV is its interaction with peptide transporter 1, commonly called PepT1.

PepT1 is a transport protein that moves small peptides from the digestive tract into intestinal cells. It is normally expressed most strongly in the small intestine but may become more active in the colon during intestinal inflammation.

Because KPV contains only three amino acids, PepT1 can transport it into certain intestinal epithelial and immune cells.

Once inside those cells, KPV may influence NF-kB, MAP kinase activity and the production of pro-inflammatory cytokines.

This transport mechanism has made KPV particularly interesting in research involving the gastrointestinal tract. It also offers a biological explanation for how such a small peptide may reach cells involved in intestinal inflammation.

Epithelial-Barrier Support

The skin and gastrointestinal lining are epithelial barriers. These tissues help separate the body from bacteria, irritants, digestive contents and other environmental exposures.

Inflammation can disrupt barrier integrity, while a weakened barrier can allow additional inflammatory triggers to reach underlying tissue.

KPV has been studied for its potential ability to help regulate inflammation within epithelial cells. Animal research has also examined its effects on tissue healing in the digestive tract, skin and cornea.

By supporting a more balanced inflammatory environment, KPV may help create conditions that are more favorable for barrier maintenance and recovery.

Antimicrobial Activity

KPV has demonstrated antimicrobial activity in laboratory research.

Early studies found that KPV and related alpha-MSH peptides could inhibit the growth of Staphylococcus aureus and Candida albicans. These organisms are commonly associated with bacterial and fungal infections affecting barrier tissues such as the skin and mucous membranes.

Researchers have proposed that the peptide may interfere with microbial energy regulation and cellular function.

This combination of anti-inflammatory and antimicrobial activity is notable because inflammation and microbial imbalance frequently overlap in the skin and gastrointestinal tract.

These laboratory findings do not establish KPV as a treatment for human infections, but they help explain the peptide’s broader role in research involving barrier defense and immune regulation.

What Does the Research Say About KPV?

KPV has been studied in laboratory experiments, human-derived cells and tissues, and animal models. Direct clinical research involving KPV administration in people has not yet been established.

Laboratory Research

Laboratory studies have helped researchers examine how KPV influences individual cells, signaling pathways and microorganisms.

These experiments have associated KPV with:

• Reduced NF-kB activation
• Reduced MAP kinase signaling
• Lower expression of certain pro-inflammatory cytokines
• Modulation of immune-cell activity
• Uptake through the PepT1 transporter
• Antimicrobial activity
• Epithelial-cell protection
• Wound-repair signaling

In one frequently cited study, researchers evaluated KPV in human intestinal epithelial cells and human T cells. The peptide reduced inflammatory signaling at very low concentrations, and its activity was connected to cellular uptake through PepT1.

Other laboratory research found that KPV influenced inflammatory responses in macrophage-like cells without relying on the same melanocortin-receptor activity associated with full-length alpha-MSH.

KPV has also been evaluated in human cadaver skin. Researchers found that its ability to move through intact skin was limited, but techniques such as microporation and iontophoresis increased its penetration into deeper epidermal layers.

These findings may inform the development of future topical delivery methods.

Animal Research

Animal studies represent a significant portion of the current KPV evidence.

Researchers have evaluated KPV in models involving:

• Intestinal inflammation
• Experimental colitis
• Localized tissue inflammation
• Skin and corneal wounds
• Swelling and inflammatory responses
• Cytokine activity
• Barrier-tissue recovery

In a 2008 study, oral KPV reduced inflammatory activity in two mouse models of colitis. Researchers observed reductions in inflammatory-cell activity and pro-inflammatory cytokine expression.

The same study found that KPV’s effects were connected to PepT1, supporting the theory that intestinal peptide transport plays an important role in its activity.

Researchers have also evaluated KPV in experimental wound-healing models. One study involving corneal injuries found that the peptide supported epithelial healing through a process associated with nitric oxide signaling.

Other animal studies have demonstrated reduced swelling and inflammatory activity following KPV administration.

Together, these findings provide much of the scientific foundation for KPV’s reputation as an inflammation-focused peptide.

Human Research

As of August 2026, published clinical research involving KPV administration in humans remains limited.

The FDA’s 2026 scientific review did not identify clinical trials or human-exposure studies evaluating KPV free base or KPV acetate through topical, oral or injectable administration.

Some KPV research has involved human-derived intestinal cells, immune cells, neutrophils and cadaver skin. These studies provide useful information about biological mechanisms and delivery, but they are not the same as clinical trials in living participants.

The absence of direct human trials does not erase the encouraging preclinical findings. It does mean that researchers still need to determine:

• How KPV behaves in the human body
• Which formulations and delivery methods are most effective
• Which applications are most promising
• How dosing affects biological activity
  

KPV’s growing visibility and recent regulatory attention may help encourage more direct human research.

KPV vs. Alpha-MSH

KPV and alpha-MSH are closely related, but they are not identical.

Alpha-MSH is a naturally occurring peptide composed of 13 amino acids. It participates in pigmentation, immune regulation, inflammatory signaling and several other physiological processes.

KPV contains only the final three amino acids of alpha-MSH.

The central portion of alpha-MSH contains the sequence primarily responsible for activating melanocortin receptors involved in pigmentation. KPV does not include that complete central sequence.

Experimental research suggests that KPV can retain anti-inflammatory activity without producing the same pigmentation-related response associated with full-length alpha-MSH.

KPV also appears to influence inflammation through mechanisms that do not depend entirely on traditional melanocortin-receptor activation. These may include:

• Inhibition of NF-kB
• Regulation of inflammatory cytokines
• Interaction with MAP kinase pathways
• Cellular uptake through PepT1
• Direct antimicrobial activity

This distinction is one of the main reasons researchers became interested in KPV. It may offer a more focused way to investigate alpha-MSH-related inflammatory activity without reproducing every biological effect of the complete peptide.

Is KPV FDA-Approved?

As of August 2026, KPV is not an FDA-approved medication, but it recently received an encouraging regulatory recommendation.

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding both KPV free base and KPV acetate to the Section 503A Bulks List.

If the FDA adopts the recommendation, licensed compounding pharmacies would have a clearer regulatory pathway to prepare KPV medications for individual patients with valid prescriptions.

The committee evaluated KPV in connection with wound healing and inflammatory conditions. Its recommendation is not the same as formal FDA approval and remains subject to a final FDA decision.

Still, the favorable vote represents meaningful progress for KPV. It also creates an opportunity for more structured physician-supervised access and may encourage additional research into the peptide’s potential clinical applications.

More information is available through the FDA’s July 2026 advisory committee materials and KPV briefing document.

What Does Compounded KPV Mean?

A compounded medication is prepared by a licensed pharmacy or qualified compounding facility based on a healthcare provider’s prescription.

Compounding allows a medication to be prepared in a particular strength or formulation as part of an individualized treatment plan.

KPV may be incorporated into a compounded therapy by itself or alongside other peptides with complementary biological functions. The selected formulation, route of administration and treatment schedule depend on the prescribing provider, pharmacy and patient’s clinical goals.

Compounded medications do not go through the same FDA premarket review process as commercially approved drugs. The July 2026 advisory committee recommendation concerns whether KPV should be eligible for use in Section 503A compounding; it does not make KPV an FDA-approved medication.

The favorable recommendation is nevertheless an important regulatory development. If finalized by the FDA, it would provide a more clearly defined pathway for qualified pharmacies to prepare KPV for patients under licensed clinical supervision.

Why Are Clinicians and Researchers Interested in KPV?

KPV has attracted attention because inflammation influences many areas of health, including digestive function, skin integrity, immune activity, physical recovery and tissue repair.

Interest continues because KPV:

• Contains only three amino acids
• Is derived from the anti-inflammatory end of alpha-MSH
• Appears to retain activity without the same pigmentation response
• Influences NF-kB and MAP kinase signaling in experimental research
• May reduce the expression of several inflammatory cytokines
• Can be transported into intestinal cells through PepT1
• Has demonstrated antimicrobial activity in laboratory studies
• Has produced encouraging findings in animal models of inflammation and tissue injury
• Recently received a favorable recommendation for the 503A Bulks List

For researchers, KPV provides a relatively focused way to study the relationship between alpha-MSH, inflammation and barrier-tissue health.

Its interaction with PepT1 is especially notable because it offers a specific mechanism through which the peptide may reach inflamed intestinal cells.

For clinicians, KPV’s appeal centers on its potential ability to complement other regenerative peptides within an individualized treatment plan. Continued human research will help determine which applications, formulations and patient populations are most appropriate.

KPV Therapy at RegenMD Wellness

RegenMD Wellness offers KPV as part of its compounded Recovery Blend for eligible patients following consultation with a licensed healthcare provider.

Recovery Blend combines KPV with BPC-157, GHK-Cu and TB-500. Each peptide contributes a different but potentially complementary mechanism:

• KPV supports inflammatory and cytokine balance.
• BPC-157 supports vascular activity, gastrointestinal integrity and connective-tissue recovery.
• GHK-Cu supports collagen production and extracellular-matrix remodeling.
• TB-500 supports actin regulation, cellular movement and broader tissue repair.

Within the formulation, KPV is included to support a balanced inflammatory environment while the other peptides address additional parts of the recovery process.

This combination may be considered for patients whose goals involve tissue recovery, mobility, physical resilience or regenerative wellness.

During the consultation process, a RegenMD provider reviews factors such as:

• Medical history
• Current medications and supplements
• Previous injuries or procedures
• Current symptoms
• Recovery and wellness goals
• Allergies and potential risk factors
• Previous treatments
• Appropriate treatment monitoring

If a KPV-containing therapy is considered appropriate, the provider establishes the formulation, dose, schedule, treatment length and follow-up plan for that patient.

Eligibility is determined through the clinical evaluation, and completing a consultation does not guarantee that a particular treatment will be prescribed. Patients who begin therapy should follow their provider’s instructions and communicate any health changes or questions throughout the treatment process.

This article is provided for general educational purposes and does not constitute medical advice. Research discussed may include laboratory, animal, and human studies. Patients should always consult a licensed clinician when considering peptide therapy.

Sources

• Hiltz ME, Lipton JM. “Antiinflammatory Activity of a COOH-Terminal Fragment of the Neuropeptide Alpha-MSH.” FASEB Journal. 1989.
• Brzoska T, et al. “Alpha-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects In Vitro and In Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases.” Endocrine Reviews. 2008.
• Luger TA, Brzoska T. “Alpha-MSH Related Peptides: A New Class of Anti-Inflammatory and Immunomodulating Drugs.” Annals of the Rheumatic Diseases. 2007.
• Getting SJ, Schiöth HB, Perretti M. “Dissection of the Anti-Inflammatory Effect of the Core and C-Terminal KPV Alpha-Melanocyte-Stimulating Hormone Peptides.” Journal of Pharmacology and Experimental Therapeutics. 2003.
• Dalmasso G, et al. “PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation.” Gastroenterology. 2008.
• Bonfiglio V, et al. “Effects of the COOH-Terminal Tripeptide Alpha-MSH(11–13) on Corneal Epithelial Wound Healing: Role of Nitric Oxide.” Experimental Eye Research. 2006.
• Cutuli M, et al. “Antimicrobial Effects of Alpha-MSH Peptides.” Journal of Leukocyte Biology. 2000.
• Catania A, et al. “The Neuropeptide Alpha-MSH in Host Defense.” Annals of the New York Academy of Sciences. 2000.
• Pawar K, et al. “Transdermal Iontophoretic Delivery of Lysine-Proline-Valine KPV Peptide Across Microporated Human Skin.” Journal of Pharmaceutical Sciences. 2017.
• Böhm M, Luger TA. “Are Melanocortin Peptides Future Therapeutics for Cutaneous Wound Healing?.” Experimental Dermatology. 2019.
• U.S. Food and Drug Administration. “Pharmacy Compounding Advisory Committee Briefing Document for KPV-Related Bulk Drug Substances.” May 2026.
• U.S. Food and Drug Administration. “July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.” July 2026.
• U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.”